Curis | CRIS - Assets


Curis reported $19.97M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
CSL USD 37.9B 1.5B Dec/2025
Curis USD 19.97M 9.27M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Exelixis USD 2.59B 250.83M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Takeda JPY 15.45T 44.34B Mar/2026
TG Therapeutics USD 1.53B 465.58M Mar/2026
Verastem USD 246.44M 69.59M Dec/2025
Xoma USD 263.15M 39.7M Sep/2025